Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR).
Adverse events
CLINICAL PHARMACOLOGY
Dermatological epidemiology
EPIDEMIOLOGY
IMMUNOLOGY
PREVENTIVE MEDICINE
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
17 08 2022
17 08 2022
Historique:
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
20
8
2022
Statut:
epublish
Résumé
Severe cutaneous adverse reactions (SCAR) are a group of T cell-mediated hypersensitivities associated with significant morbidity, mortality and hospital costs. Clinical phenotypes include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalised exanthematous pustulosis (AGEP). In this Australasian, multicentre, prospective registry, we plan to examine the clinical presentation, drug causality, genomic predictors, potential diagnostic approaches, treatments and long-term outcomes of SCAR in Australia and New Zealand. Adult and adolescent patients with SCAR including SJS, TEN, DRESS, AGEP and another T cell-mediated hypersensitivity, generalised bullous fixed drug eruption, will be prospectively recruited. A waiver of consent has been granted for some sites to retrospectively include cases which result in early mortality. DNA will be collected for all prospective cases. Blood, blister fluid and skin biopsy sampling is optional and subject to patient consent and site capacity. To develop culprit drug identification and prevention, genomic testing will be performed to confirm human leukocyte antigen (HLA) type and ex vivo testing will be performed via interferon-γ release enzyme linked immunospot assay using collected peripheral blood mononuclear cells. The long-term outcomes of SCAR will be investigated with a 12-month quality of life survey and examination of prescribing and mortality data. This study was reviewed and approved by the Austin Health Human Research Ethics Committee (HREC/50791/Austin-19). Results will be published in peer-reviewed journals and presented at relevant conferences. Australian New Zealand Clinical Trials Registry (ACTRN12619000241134).
Identifiants
pubmed: 35977774
pii: bmjopen-2021-055906
doi: 10.1136/bmjopen-2021-055906
pmc: PMC9389100
doi:
Banques de données
ANZCTR
['ACTRN12619000241134']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e055906Subventions
Organisme : NIAID NIH HHS
ID : UM1 AI109565
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG010863
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI152183
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 AI152183
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI154659
Pays : United States
Organisme : NIAMS NIH HHS
ID : R13 AR078623
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Mol Sci. 2017 Aug 10;18(8):
pubmed: 28796198
Clin Biochem Rev. 2013 Feb;34(1):15-38
pubmed: 23592889
Int J Dermatol. 2014 Nov;53(11):1339-45
pubmed: 25070588
J Allergy Clin Immunol Pract. 2021 Feb;9(2):929-936.e7
pubmed: 32961314
Ann Allergy Asthma Immunol. 2011 Apr;106(4):330-5
pubmed: 21457882
Clin Pharmacol Ther. 2011 Jun;89(6):806-15
pubmed: 21544079
J Allergy Clin Immunol Pract. 2019 Jan;7(1):219-227.e4
pubmed: 29800753
Int J Dermatol. 2013 May;52(5):575-9
pubmed: 23330601
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1341-1343.e1
pubmed: 30266590
Lancet. 2019 Jan 12;393(10167):183-198
pubmed: 30558872
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69
pubmed: 29310768
J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1187-1193
pubmed: 27283055
Clin Infect Dis. 2014 May;58(10):1377-85
pubmed: 24599767
J Allergy Clin Immunol. 2019 Jan;143(1):66-73
pubmed: 30573342
N Engl J Med. 2008 Feb 7;358(6):568-79
pubmed: 18256392
J Allergy Clin Immunol Pract. 2019 Jan;7(1):228-230
pubmed: 30598178
Allergy. 2007 Dec;62(12):1439-44
pubmed: 17983378
J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1287-1296.e1
pubmed: 29100867
Front Pharmacol. 2021 Jan 12;11:573573
pubmed: 33597867
J Allergy Clin Immunol Pract. 2021 May;9(5):2010-2015.e4
pubmed: 33453452
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Lancet. 2017 Oct 28;390(10106):1996-2011
pubmed: 28476287
Br J Dermatol. 2013 Nov;169(5):1071-80
pubmed: 23855313
Curr Opin Infect Dis. 2016 Dec;29(6):561-576
pubmed: 27753687
J Immunol. 2014 Apr 1;192(7):2984-93
pubmed: 24591375